Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03056755 |
|---|---|
| Brief Title: | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve) |
| First Submitted : | February 15, 2017 |
| First Submitted that Met QC Criteria : | February 15, 2017 |
| First Posted : | February 17, 2017 |
| Results First Submitted : | February 29, 2024 |
| Results First Submitted that Met QC Criteria : | February 29, 2024 |
| Results First Posted : | March 27, 2024 |
| Certification/Extension First Submitted : | May 13, 2022 |
| Certification/Extension First Submitted that Met QC Criteria : | May 13, 2022 |
| Certification/Extension First Posted : | May 16, 2022 |
| Last Update Submitted that Met QC Criteria : | February 29, 2024 |
| Last Update Posted : | March 27, 2024 |